Verinata Health announced the launch of its expanded verifi prenatal test to detect the most common fetal sex chromosome abnormalities.
On November 6, the company announced the expansion of verifi’s prenatal test capabilities. The optional expansion now includes detection of Turner syndrome (Monosomy X), Trisomy X (XXX), Klinefelter syndrome (XXY) and XYY syndrome, the most common fetal sex chromosome abnormalities.The verifi test detects Down syndrome (trisomy 21 or T21), Edwards syndrome (trisomy 18 or T18) and Patau syndrome (trisomy 13 or T13). This test can also aid in the diagnosis of X-linked disorders (eg, hemophilia, Duchenne muscular dystrophy or cases of congenital adrenal hyperplasia).
The verifi prenatal test utilizes massively parallel sequencing (MPS) with a highly-optimized algorithm to provide results for chromosomes 21, 18, and 13 as well as the sex chromosomes.
For more information call (855) 266-6563 or visit www.verinata.com.